What Cannabis Products Affect Superbugs and Vaccines?

Article by Travis Cesarone, Cannabis Life Network

WHAT CANNABIS PRODUCTS AFFECT SUPERBUGS AND VACCINES? TRAVIS CESARONEMARCH 12, 2021 CANNABIS 101CANNABIS LEGALIZATIONEDUCATIONFEATUREDHEALTHLAWMARIJUANA NEWSPRODUCTSSCIENCETECHNOLOGY0 COMMENTS0 VIEWS Cannabis can agonize PPARs, a messenger protein that regulates lipid and inflammatory homeostasis and inhibits common cold symptoms. (1) Moreover, Lethbridge University discovered significantly reduced cytokine levels in chronic cannabis users that led to drastically decreased viral severity. (2) And, on the bacteria front, cannabis can effectively fight off bacterial infections. So, what cannabinoid or cannabis products affect superbugs and vaccines, and how do any hurt overall health?

Cannabis can agonize PPARs, a messenger protein that regulates lipid and inflammatory homeostasis and inhibits common cold symptoms. (1) Moreover, Lethbridge University discovered significantly reduced cytokine levels in chronic cannabis users that led to drastically decreased viral severity. (2) And, on the bacteria front, cannabis can effectively fight off bacterial infections. So, what cannabinoid or cannabis products affect superbugs and vaccines, and how do any hurt overall health?

The link is in the process. In fact, no plants need to be involved in the origin of these cannabinoids.

Fermenting cannabinoids

A previous report covered a conversation with Organigram’s former Senior Marketing Director, Ray Gracewood. This detailed their now released dissolving cannabinoid product, a drink mix powder.

In our phone call, I asked Ray Gracewood if the cannabinoids in their drink mix powder were grown [out of yeast] with their Hyasynth Biologicals partnership, instead of cannabis.

They come from different strains.

Ray Gracewood

It was announced that different strains of yeast are going to drive the cannabinoid production for Organigram’s vape pens, topicals, and edibles. (3) Strains of bacteria, such as E. Coli, can also be used to produce cannabis, according to definitions in the Cannabis Act. (4) Or, of course, strains of cannabis plants could be used to make cannabis but possibly at a greater expense. In full, Organigram and Hyasynth have yet to release their intellectual property.

Trade-secret sources behind proprietary mixes

To find out more, we sent Organigram and their current Interim Director of Brand, Eric Williams, a direct email. We received no response. But, it was a Public Relations company that Organigram contracts, Gage Communications, who contacted me to pitch the previous interview with Ray in 2019. So, I forwarded my email to Gage Communications and asked for an update. Their President, Marlo Taylor, had this to say on behalf of Organigram regarding the origin of their cannabinoids.

Cannabinoids in the ReMix product are extracted from cannabis plants.

Marlo Taylor on behalf of Organigram.

Can you further describe other strains that are used in your drink mix powder, ReMix?

Cannabis distillate, [produced by synthesis, manufacture, or chemical alteration] from various strains (either CBD or THC dominant depending on the end product) is processed into a nanoemulsion…

Like Organigram’s other product offerings, ReMix meets composition and quality requirements set out by Health Canada. These requirements relate to accuracy of labeled claims and microbial/chemical contaminant levels, among other things, and do not specifically address the origin of cannabinoids (i.e. biosynthetic, synthetic, plant-based) or how refined cannabinoids must be when added into a mixture.

Marlo Taylor.

Thank you for your response, Marlo.

Please note the added definition from within the Cannabis Act, which is included inside parentheses ‘[]’ for your courtesy. (4) In the Cannabis Act’s definitions, ‘cannabis’ can refer to a synthetic or biosynthetic cannabinoid, unless the term, ‘cannabis plant’ is specified.

The founder of Hyasynth Biologicals, Kevin Chen, told Project CBD that they were still in the research and development phase one year ago, (5) which Organigram invested another $2.5 million into last November. They plan to invest a final $2.5 million once Hyasynth achieves another milestone, according to a press release. (6)

Furthermore, Health Canada only regards a finite list of contaminants in cannabis products and does not consider the source. Given that fact, is it possible that cannabinoids grown out of yeast, too unrefined or too uncertain to release, are secretly added to Health Canada licensed products? Would anyone truly sell impure cannabinoids without the public’s knowledge, as opposed to waste any cannabinoids that were adequately produced in their R&D process?

It seems unlikely if we consider the impact an adverse reaction might have on any company.

Health Canada’s eye is blind on the subject, so we simply do not know.

Unfortunately, the source of some Licensed Cultivator’s cannabinoids is not only hidden from public knowledge, Health Canada remains willfully ignorant on the subject. (4) The focal point of this argument, however, is undisclosed control agents that can be used by licensed processors. These agents help mitigate contamination during the production of unrefined yeast-derived cannabinoids.

Control agents are commonly added to the media (starting material) and are regulated by the Canadian Food Inspection Agency (CFIA) in conjunction with Health Canada.

Read the full article here.

About Dankr NewsBot

Beep Boop. I'm just a bot who brings you the dankest news in the biz

Leave a Reply

Powered by Dragonballsuper Youtube Download animeshow